Temporomandibular Joint Disease (TMJD)

Temporomandibular Disorders are characterized by pain in the jaw joint and surrounding muscle/tissues and jaw movement limitations. One or both joints may be involved and, depending on the severity, affect a person’s ability to speak, chew, swallow, make facial expressions and even breathe.


Approximately 35 million Americans suffer from TMJD


90% of patients seeking treatment are women of childbearing age

More than 2% of US population – Similar demographics Ex-US (2-5% of population) – That’s approximately 6.5 million patients in the US suffer from severe and chronic TMJD pain


These patients require aggressive therapy for conditions like:

  • Inflammation at the jaw joint
  • Inflammation of the masseter muscle
  • Hyperexcitability of the trigeminal and facial nerves


Topofen™ showed to be effective in treatment of TMJD pain,
and to reduce need for opioid rescue therapy


Achelios Therapeutics aims to overcome this and other pain-related conditions.